The Filing Desk

UFP Technologies

UFPT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

UFPT · Last close · November 6, 2026
$303.47
Value UFP Technologies yourself

UFP Technologies' revenue rose 19.5% to $603 million in fiscal 2025. Its operating margin was 15.3%, down from 16.0% a year earlier. The diluted share count rose 0.2%.

UFP Technologies, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001628280-26-012816 Updated
Revenue
$603M
19.5%
Operating margin
15.3%
0.7 pts
Net income
$68M
15.8%
Free cash flow
—
 
Return on capital
14.4%
1.3 pts
Market cap
$2.4B
Nov 6 close
P/E
30.9x
On $9.81 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. UFP Technologies' 2025 filing doesn't tag its capital spending under the usual label, so capital spending and free cash flow are blank for 2025.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 25.9% a year and net income 26.9% a year, as new shares raised the share count by 7% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments11451320
Debt incl. finance leases755532190136
Net debt (negative means net cash)645127176115
Net debt to EBITDA2.2x0.8x0.4x1.8x1.0x
Debt to equity0.4x0.2x0.1x0.6x0.3x
Interest coverage544.0x20.1x15.8x10.0x9.4x
Current ratio2.2x2.1x2.5x2.6x2.7x
Quick ratio1.4x1.1x1.3x1.4x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project UFP Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 7, 2025 and November 6, 2026, no insider bought UFP Technologies shares on the open market, and 6 insiders sold $13.6 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 25, 2026Marc D KozinDirectorSold7,000$304.50$2.1 millionForm 4
Aug 18, 2026Symeria HudsonDirectorSold298$319.11$95,095Form 4
Aug 14, 2026Symeria HudsonDirectorSold1,926$324.58$625,141Form 4
Aug 13, 2026Cynthia L FeldmannDirectorSold1,000$324.26$324,260Form 4
Aug 10, 2026Bailly R JeffreyExecutive Chairman, DirectorSold13,011$316.13$4.1 millionForm 4
Aug 7, 2026Bailly R JeffreyExecutive Chairman, DirectorSold5,013$317.87$1.6 millionForm 4
Aug 6, 2026Bailly R JeffreyExecutive Chairman, DirectorSold10,682$318.63$3.4 millionForm 4
Aug 6, 2026Jason HoltVice PresidentSold1,100$317.00$348,700Form 4
Jun 12, 2026Cynthia L FeldmannDirectorSold1,200$239.29$287,149Form 4
May 12, 2026Daniel C CroteauDirectorSold2,864$221.71$634,977Form 4
Dec 10, 2025Jason HoltVice PresidentSold100$213.58$21,358Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 97 of 95 of 9
Rule of 4020.8%37.4%—
Altman Z''6.904.956.00
Accruals ratio0.9%−1.5%−3.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailPassFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassFailPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsFailPassFail
F-score5 of 97 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put UFP Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
UFP TechnologiesFY2519.5%15.3%—14.4%1.0x5
TransMedics GroupFY2537.1%17.9%22.1%27.5%−0.2x7Compare
GlaukosFY2532.3%−39.3%−4.4%———Compare
ArtivionFY2513.6%7.7%0.2%3.9%2.7x7Compare
Inspire Medical SystemsFY2513.6%5.6%8.6%14.2%−4.8x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue146148190198179206354400504603
Revenue growth5.2%1.2%28.8%4.2%−9.6%15.0%71.5%13.1%26.1%19.5%
Gross profit35364854455190112147170
Research and development151098897109
Operating income12122025172155588192
Net income891420131642455968
Diluted EPS (US$)1.101.261.932.631.772.095.455.837.588.75
Diluted shares (millions)7778888888
Cash flow
Cash from operations9182131251418416792
Capital expenditure7105645141010—
Free cash flow27162521943157—
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0077009621019815
Stock-based compensation1112223579
Balance sheet at fiscal year end
Cash and short-term investments3138342411451320
Debt incl. finance leases1—25—0755532190136
Total assets128138190189203334378404629655
Total liabilities1514492726140141118286231
Shareholders' equity113124140162177194238286343424
Margins and ratios
Gross margin23.7%24.0%25.4%27.2%24.9%24.8%25.5%28.1%29.1%28.3%
Operating margin8.4%7.9%10.3%12.4%9.3%10.3%15.7%14.4%16.0%15.3%
Net margin5.5%6.2%7.5%10.0%7.5%7.7%11.8%11.2%11.7%11.3%
Free cash flow margin1.4%4.8%8.3%12.8%11.5%4.3%1.1%7.7%11.3%—
Rule of 40 (growth + FCF margin)6.7%6.0%37.2%17.0%1.9%19.3%72.6%20.8%37.4%—
Return on capital10.0%————7.7%16.1%16.0%15.7%14.4%
Return on equity7.4%7.8%10.8%13.1%7.9%8.6%19.4%17.2%18.8%17.8%
Return on assets6.4%6.9%8.7%10.4%6.8%5.9%11.7%11.5%11.4%10.6%
Net debt to EBITDA−1.7x—0.8x—−1.0x2.2x0.8x0.4x1.8x1.0x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: UFP Technologies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with UFP Technologies.